CN1304449A - 新血管紧张肽受体,其制备和用途 - Google Patents
新血管紧张肽受体,其制备和用途 Download PDFInfo
- Publication number
- CN1304449A CN1304449A CN99807126A CN99807126A CN1304449A CN 1304449 A CN1304449 A CN 1304449A CN 99807126 A CN99807126 A CN 99807126A CN 99807126 A CN99807126 A CN 99807126A CN 1304449 A CN1304449 A CN 1304449A
- Authority
- CN
- China
- Prior art keywords
- sequence
- seq
- nucleic acid
- angiotensin receptors
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108050000824 Angiotensin II receptor Proteins 0.000 title claims abstract description 60
- 102000008873 Angiotensin II receptor Human genes 0.000 title claims abstract description 58
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 20
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 15
- 239000002299 complementary DNA Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 108010021724 tonin Proteins 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 210000000748 cardiovascular system Anatomy 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 230000008676 import Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 22
- 239000000370 acceptor Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 14
- 238000013467 fragmentation Methods 0.000 description 11
- 238000006062 fragmentation reaction Methods 0.000 description 11
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 8
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- 102400000345 Angiotensin-2 Human genes 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 108010072661 Angiotensin Amide Proteins 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- VLAFRQCSFRYCLC-FXQIFTODSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-2-aminopropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]pentanedioic acid Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VLAFRQCSFRYCLC-FXQIFTODSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229930183912 Cytidylic acid Natural products 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- ZQYZDDXTNQXUJH-CIUDSAMLSA-N Glu-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)N ZQYZDDXTNQXUJH-CIUDSAMLSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- SMVTWPOATVIXTN-NAKRPEOUSA-N Met-Ser-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SMVTWPOATVIXTN-NAKRPEOUSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 1
- LXVLKXPFIDDHJG-CIUDSAMLSA-N Pro-Glu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O LXVLKXPFIDDHJG-CIUDSAMLSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- JZWZACGUZVCQPS-RNJOBUHISA-N Val-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N JZWZACGUZVCQPS-RNJOBUHISA-N 0.000 description 1
- 108010069490 alanyl-glycyl-seryl-glutamic acid Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 102220369446 c.1274G>A Human genes 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102220023256 rs387907547 Human genes 0.000 description 1
- 102220023258 rs387907548 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19825494.6 | 1998-06-08 | ||
| DE19825494A DE19825494A1 (de) | 1998-06-08 | 1998-06-08 | Neuer Angiotensin Rezeptor, Herstellung und Verwendung desselben |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1304449A true CN1304449A (zh) | 2001-07-18 |
Family
ID=7870244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99807126A Pending CN1304449A (zh) | 1998-06-08 | 1999-05-12 | 新血管紧张肽受体,其制备和用途 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1086217A2 (pt) |
| JP (1) | JP2002517237A (pt) |
| KR (1) | KR20010052703A (pt) |
| CN (1) | CN1304449A (pt) |
| AR (1) | AR020086A1 (pt) |
| AU (1) | AU4361699A (pt) |
| BR (1) | BR9912183A (pt) |
| CA (1) | CA2330229A1 (pt) |
| DE (1) | DE19825494A1 (pt) |
| HU (1) | HUP0102540A3 (pt) |
| ID (1) | ID27566A (pt) |
| PL (1) | PL345949A1 (pt) |
| TR (1) | TR200003662T2 (pt) |
| WO (1) | WO1999064585A2 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005017807D1 (de) * | 2004-10-21 | 2009-12-31 | Medtronic Inc | Angiotensin-(1-7) freisetzende polymerbeschichtete medizinische vorrichtung zur reduzierung von restenose und zur verbesserung von endothelzellfunktionen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA934536B (en) * | 1992-06-24 | 1994-02-03 | Univ Washington | Angiotensin IV peptides and receptors |
-
1998
- 1998-06-08 DE DE19825494A patent/DE19825494A1/de not_active Withdrawn
-
1999
- 1999-05-12 KR KR1020007013967A patent/KR20010052703A/ko not_active Application Discontinuation
- 1999-05-12 HU HU0102540A patent/HUP0102540A3/hu unknown
- 1999-05-12 CN CN99807126A patent/CN1304449A/zh active Pending
- 1999-05-12 WO PCT/EP1999/003249 patent/WO1999064585A2/de not_active Application Discontinuation
- 1999-05-12 JP JP2000553575A patent/JP2002517237A/ja not_active Withdrawn
- 1999-05-12 PL PL99345949A patent/PL345949A1/xx not_active Application Discontinuation
- 1999-05-12 CA CA002330229A patent/CA2330229A1/en not_active Abandoned
- 1999-05-12 BR BR9912183-2A patent/BR9912183A/pt not_active IP Right Cessation
- 1999-05-12 EP EP99926305A patent/EP1086217A2/de not_active Withdrawn
- 1999-05-12 TR TR2000/03662T patent/TR200003662T2/xx unknown
- 1999-05-12 AU AU43616/99A patent/AU4361699A/en not_active Abandoned
- 1999-06-04 AR ARP990102666A patent/AR020086A1/es unknown
- 1999-12-07 ID IDW20002553A patent/ID27566A/id unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102540A3 (en) | 2003-09-29 |
| JP2002517237A (ja) | 2002-06-18 |
| KR20010052703A (ko) | 2001-06-25 |
| BR9912183A (pt) | 2001-04-10 |
| WO1999064585A2 (de) | 1999-12-16 |
| ID27566A (id) | 2001-04-12 |
| AR020086A1 (es) | 2002-04-10 |
| EP1086217A2 (de) | 2001-03-28 |
| HUP0102540A2 (hu) | 2001-10-28 |
| TR200003662T2 (tr) | 2001-07-23 |
| AU4361699A (en) | 1999-12-30 |
| PL345949A1 (en) | 2002-01-14 |
| WO1999064585A3 (de) | 2000-04-06 |
| DE19825494A1 (de) | 1999-12-09 |
| CA2330229A1 (en) | 1999-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6524799B1 (en) | DNA encoding sparc-related proteins | |
| CA2292899A1 (en) | Ntn-2 member of tnf ligand family | |
| WO1998055620A1 (en) | Ntn-2 member of tnf ligand family | |
| CN1379816A (zh) | 人g－蛋白偶联受体 | |
| CN1198186A (zh) | 趋化因子β－8的短形式 | |
| CN1304449A (zh) | 新血管紧张肽受体,其制备和用途 | |
| AU2207999A (en) | Novel nucleic acid and polypeptide | |
| CN1353754A (zh) | 用作TNF－α信号传导途径抑制物的TRAF2变体 | |
| CN1568330A (zh) | 含有糖基化磷脂酰肌醇的嵌合多肽 | |
| CN1131309C (zh) | 白细胞介素－6突变蛋白 | |
| CN1477117A (zh) | 新型人磷脂酰乙醇胺结合蛋白，其编码序列及用途 | |
| CN1415012A (zh) | 结合人酪氨酸激酶Hck的人蛋白质及其编码基因 | |
| CN1375503A (zh) | 雄激素受体复合物相关蛋白 | |
| WO1997030156A2 (en) | NUCLEOTIDES AND PEPTIDES CORRESPONDING TO THE CANINE IgE HEAVY CHAIN CONSTANT REGION AND RELATED METHODS | |
| CN1352138A (zh) | 精子生成相关蛋白、其编码序列及用途 | |
| US20030119024A1 (en) | Genes and proteins associated with T cell activation | |
| CN1328134A (zh) | 一种蛋白激酶编码序列,其编码的多肽、制法及用途 | |
| CN1396260A (zh) | 一种牛bLATS1基因、核苷酸和蛋白的编码序列，及其制备与用途 | |
| CN1343774A (zh) | 一种癫痫相关蛋白编码序列,其编码的多肽、制法及用途 | |
| CN1325874A (zh) | 新的人c型外源凝集素样受体、其编码序列及用途 | |
| CN1374405A (zh) | 人腺苷酸环化酶相关蛋白编码序列、其制备方法及用途 | |
| CN1477193A (zh) | 新型人Rab GTP酶，其编码序列及用途 | |
| CN1396259A (zh) | 一种鸡cLATS1基因、核苷酸和蛋白的编码序列，及其制备与用途 | |
| CN1299828A (zh) | 新的细胞因子受体、其编码序列及用途 | |
| MXPA00012127A (en) | Novel angiotensin receptor, production and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1039500 Country of ref document: HK |